A large panel of biomarkers is available in the present study population, representing a wide range of pathophysiological pathways for cardiovascular disease, that is, myocardial stress, myocyte injury, inflammation, renal dysfunction, extracellular matrix markers, renin-angiotensin activation system, and other domains. 12, 13 We sought to identify and quantify the Background-We aim to identify and quantify the value of biomarkers for incident new-onset heart failure (HF) in a community-based cohort and subgroups based on cardiovascular risk and evaluate the prognostic value of 13 biomarkers for HF with reduced and preserved ejection fraction.
H eart failure (HF) is a progressive syndrome with high morbidity and one of the major causes of death in Western countries. [1] [2] [3] Since the discovery of natriuretic peptides, interest in using biomarkers alongside of clinical characteristics to guide early identification of subjects at risk has grown. 4 Several new biomarkers have emerged, but to date their clinical value remains under dispute. Proposed biomarkers include high-sensitive troponin T (hs-TnT), urinary albumin excretion (UAE) or albumin-to-creatinine ratio, and high-sensitive C-reactive protein (hs-CRP). The predictive value for new-onset HF of novel biomarkers, like midregional proadrenomedullin (MR-proADM), galectin-3, or adiponectin, has not yet been well defined. [5] [6] [7] Previous multimarker studies showed little or absent incremental value of biomarkers, including natriuretic peptides, on top of conventional clinical characteristics for predicting new-onset HF in the general population. Therefore, routine measurements are considered not cost-effective. 4, 8, 9 Identification of subgroups that might benefit from biomarker testing is suggested as a more effective strategy. 9 Another limiting factor is that most studies addressed HF in general, while we now acknowledge that HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) are distinct subtypes with different pathophysiology. Only few studies have evaluated biomarkers for HFrEF and HFpEF specifically, but all were underpowered to draw definitive conclusions and were based on prevalent cases of HF. 10, 11 value of biomarkers for the prediction of new-onset HF in a community-based cohort and in subgroups based on baseline cardiovascular risk. In addition, we evaluated the prognostic value of all biomarkers for HFrEF and HFpEF separately.
Methods

Study Population
The study was performed using the data of the PREVEND (Prevention of Vascular and Renal Endstage Disease) cohort study, which has been described elsewhere. 14, 15 In summary, from 1997 to 1998, all inhabitants of the city of Groningen, The Netherlands, aged 28 to 75 years (n=85 421) were asked to send in a first morning urine sample and complete a short questionnaire on demographics and cardiovascular disease history, and 40 856 subjects responded (47.8%). All subjects with UAE≥10 mg/L (n=7786) in their morning urine as well as a randomly selected control group with a UAE<10 mg/L (n=3395) were invited to an outpatient clinic for a detailed assessment of cardiovascular and renal risk factors, including filling out questionnaires, recording anthropometrics, and blood and urine sampling. After excluding subjects with insulin-dependent diabetes mellitus, pregnant women, and subjects unable or unwilling to participate, a total of 8592 subjects completed the screening program. For the current analysis, we excluded subjects with known HF diagnosis at baseline (n=23), leaving 8569 eligible subjects. 16 The PREVEND study was approved by the institutional medical ethics committee and conducted in accordance with the Declaration of Helsinki. All subjects provided written informed consent.
Definitions
Systolic and diastolic blood pressures were calculated as the mean of the last 2 measurements of the 2 visits, measured using an automatic Dinamap XL Model 9300 series device. Hypertension was defined as systolic blood pressure>140 mm Hg, diastolic blood pressure>90 mm Hg, or self-reported use of antihypertensive medication. Body mass index was calculated as the ratio of weight to height squared (kg/m 2 ), and obesity was defined as a body mass index≥30 kg/m 2 . Hypercholesterolemia was defined as total serum cholesterol≥6.5 mmol/L (251 mg/dL) or a serum cholesterol≥5.0 mmol/L (193 mg/dL) if a history of myocardial infarction (MI) was present or when lipidlowering medication was used. Type 2 diabetes mellitus was defined as a fasting plasma glucose≥7.0 mmol/L (126 mg/dL), a nonfasting plasma glucose≥11.1 mmol/L, or use of antidiabetic drugs. UAE was calculated as the average value from 2 consecutive 24-hour urine collections. The estimated glomerular filtration rate was estimated using the simplified Modification of Diet in Renal Disease formula. 17 Smoking was defined as current smoking or smoking cessation within the previous year. History of MI of cerebrovascular accident was defined as participant-reported hospitalization for ≥ 3 days as a result of this condition. Standard 12-lead electrocardiograms were recorded using the computer program Modular ECG Analysis System, and atrial fibrillation was defined according to Minnesota codes 8.3.1 and 8.3.3. 18 Subjects were categorized in 2 risk groups, based on the presence or absence of previous cardiovascular history (referred to as high risk and low risk, respectively). Previous cardiovascular history was defined as previous hospitalization for MI or cerebrovascular accident, or the use of antihypertensive and lipid-lowering or glucoselowering drugs at baseline assessment. Antihypertensive drugs were defined as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, or calcium antagonists. Lipid-lowering drugs were defined as any kind of statin. Glucose-lowering drugs were defined as oral antidiabetic drugs. Information on medication use was obtained from the InterAction database, a community-based pharmacy database, which contains detailed patient-specific drug prescription information on inhabitants of the city of Groningen and was linked to PREVEND data. 19 Prescription drugs were classified according to the Anatomical Therapeutic Chemical system. All PREVEND participants gave informed consent to link their data with pharmacy-dispensing data. The individual Framingham Risk Score was calculated according to D'Agostino et al. 20
Assays
At baseline, EDTA plasma samples were drawn from all participants for biomarker assessment. Aliquots of these samples stored immediately after collection at −80°C until analyses. Assays for all biomarkers in PREVEND have been described in detail elsewhere: N-terminal pro-B-type natriuretic peptide (NT-proBNP), 21 midregional pro-Atype natriuretic peptide (MR-proANP), 22 MR-proADM, 23 C-terminalpro-Endothelin-1 (CT-proET-1), 24 galectin-3, 25 hs-TnT, 26 C-terminal pro-Arginine vasopressin, referred to as copeptin, 27 procalcitonin, 28 hs-CRP, 29 cystatin-C, 23 UAE, 30 renin, 31 and aldosterone. 31 For details on all assays, see Data Supplement.
New-Onset HF
Follow-up for the present investigation was defined as the time between the baseline visit to the outpatient department and the date of new-onset HF up to January 1, 2010. Subjects were censored at the date they moved to an unknown destination or at the last date of the follow-up, whatever date came first. Information on dates and causes of death for every participant (both outpatient and hospitalization data) was obtained from Statistics Netherlands 32 and coded according to the 10th revision of the International Classification of Diseases. Participants with a new diagnosis of HF were identified using criteria described in the HF Guidelines of the European Society of Cardiology 33 and an end point adjudication committee ascertained the diagnosis of either HFrEF or HFpEF, as described elsewhere. 16 HF was classified as HFrEF or HFpEF based on left ventricular ejection fraction at the time of diagnosis. left ventricular ejection fraction data were available through imaging techniques, such as echocardiography, MRI, or radionuclide ventriculography. To prevent blending and dilution of epidemiological risk profiles between HFrEF and HFpEF, and to acknowledge the most recent trends in cut-off for HFrEF and HFpEF in accordance with the HF guidelines, 33 we have set the cutoff for HFpEF on ≥50% and the cut-off for HFrEF on ≤40%. Subjects in the gray area, with a left ventricular ejection fraction 41% to 49% (n=8), were excluded from the analyses to prevent blending and dilution of differential epidemiological profiles.
Statistical Analysis
By design, subjects with an UAE≥10 mg/L are overrepresented in the PREVEND (69.8%). A design-based analysis was performed to overcome this overselection of subjects with elevated UAE. This statistical weighting method allows conclusions to be generalized to the general population. 23, 34 Baseline continuous data are reported as mean (SD) for normally distributed data. Because of skewed distribution, NT-proBNP, MR-proANP, galectin-3, hs-TnT, copeptin, procalcitonin, hs-CRP, UAE, cystatin-C, renin, and aldosterone were transformed to a 2-log scale and reported as median (interquartile range). This means that risk estimates should be interpreted as the relative risk if values were doubled (eg, 1-2 mg/L or 10-20 mg/24 h). To evaluate time to HF diagnosis for both risk groups, we performed survival analyses (Kaplan-Meier; log-rank) using cumulative incidence. To competing, end points were distinguished: HFrEF and HFpEF. We fitted Coxproportional hazards models to the data and adjusted our multivariate model for age, sex, body mass index, smoking status, systolic blood pressure, atrial fibrillation, plasma glucose, and total cholesterol levels, in accordance with previous results. 16 Schoenfeld residuals were calculated to assess whether proportionality assumptions were satisfied. We evaluated a P-value for interaction (P int ) between both risk groups to compare the effects of biomarkers between both groups. To control for the type I error in the cause-specific hazard analysis (effect-by-covariate), a P int between the high-and low-risk group of <0.10 is considered statistically significant. 16, 35 To define the proportion of usable subject pairs in which outcome and prediction are concordant, we calculated the Harrell C coefficient for both models and the incremental value of biomarkers on this coefficient. Results are summarized as hazard ratios (HRs), with 95% confidence intervals based on robust standard error estimates. We accounted for multiple testing using Bonferroni correction: for each risk group, 13 biomarkers were tested, and a P≤0.004 (=0.05/13) was considered statistically 
Results
Baseline characteristics for both risk groups are presented in Table 1 . Subjects in the high-risk group (n=1654, 19.3% of the total population) were older, more often men, had higher body mass index, blood pressure, and heart rate, and worse renal function compared with subjects in the low-risk group (n=6915). Glucose, lipid parameters, and all evaluated biomarkers were also higher at baseline for subjects in the high-risk group (P<0.001), with the exception of aldosterone (P=0.696). The calculated median Framingham Risk Score was >3 times higher in the high-risk group (18.6% versus 5.9%; P<0.001). During a median follow-up of 12.5 years (range, 12.2-12.9; over 107 000 subject years), 374 individuals were diagnosed with new-onset HF, of whom 168 (2.4%) and 206 (12.2%) were in the low-risk group and high-risk group, respectively. The median time to end point was 8.6 (range, 4.8-10.9) years in the low-risk group and 7.3 (range, 3.5-10.0) years in the high-risk group (P=0.002). Figure 1 shows the cumulative incidence of new-onset HF, divided by risk group and adjusted for all-cause mortality. Table 2 summarizes the results of the Cox-proportional hazard analysis for all biomarkers on new-onset HF (unstratified for risk groups, nor for HFrEF and HFpEF). After adjustment for age and sex, NT-proBNP, MR-proANP, hs-TnT, hs-CRP, cystatin-C, and UAE were significantly associated with increased risk for new-onset HF. In multivariate analysis, the same biomarkers remained statistically significant. The proportionality assumptions for every biomarker in the model for total HF were satisfied (P>0.100).
New-Onset HF
HRs for new-onset HF, stratified for low and high risk, and their given interaction are depicted in Figure 2A . After multivariable adjustment, higher NT-proBNP was associated with increased risk for new-onset HF in both risk groups, although this association was significantly stronger for NT-proBNP in the high-risk group (P int =0.005). There was also an interaction present for the biomarkers MR-proANP, MR-proADM, CT-proET-1, and galectin-3 (all P int <0.005; P int <0.05 for galectin-3), indicating an increased risk for new-onset HF specifically in subjects in the high-risk category at baseline. Higher values of these biomarkers were not associated with risk for new-onset HF in subjects in the low-risk group. For hs-TnT, hs-CRP, UAE, and cystatin-C, there was no interaction present, indicating that these markers are equally associated with outcome in both risk groups. Copeptin, procalcitonin, renin, and aldosterone showed no association with increased risk for new-onset HF.
The relative additional value of each biomarker to the model, compared with age and sex alone, was subsequently calculated and summarized in Table 3 . For the low-risk group, NT-proBNP, hs-CRP, and UAE modestly improved model fit by 6.1%, 4.3%, and 2.0%, respectively; other biomarkers did not improve the model. The model for subjects with high baseline risk improved with the addition of NT-proBNP, hs-TnT, MR-proANP, UAE, and galectin-3, in order of incremental value.
During the follow-up period, there were 169 MIs, which was followed by new-onset HF in 43 (25.4%) subjects (n=26 in the low-risk group; n=17 in the high-risk group, see Table I in the Data Supplement). A subanalysis was performed without these 43 subjects, to account for possible bias in the risk association for all separate biomarkers with MI, instead of new-onset HF, HFrEF, or HFpEF. This did not change the results.
HFrEF Versus HFpEF
HRs for all biomarkers in both risk groups and their potential interaction are presented in Figure 2B (HFrEF) and Figure 2C (HFpEF). Results for new-onset HFrEF were comparable to total new-onset HF, where the same biomarkers were associated with increased risk for HFrEF in subjects with high baseline cardiovascular risk. For new-onset HFpEF, there was an interaction present between risk groups for MR-proADM and CT-proET-1. However, the associated risk for HFpEF itself was not significant in both risk groups separately. Kidney function, represented by cystatin-C, was associated with new-onset HFpEF, with comparable HRs for both risk groups at baseline. The proportionality assumptions for every biomarker in the models for HFrEF and HFpEF were satisfied (P>0.100).
Model Performance
The model with best performance for the prediction of newonset HF in the entire cohort was achieved by the combination of NT-proBNP, hs-TnT, and UAE, which significantly increased model accuracy by 9.5% to 0.81 (P<0.001). These biomarkers were subsequently assessed in a multimarker score and dichotomized according to 75th percentile. Table 4 shows the univariate and multivariate HRs (for total new-onset HF) for the different combinations of the high and low values of these 3 biomarkers. All 3 entities alone were not associated with an increased risk for total new-onset HF, whereas the combination of any 2 entities increased the risk substantially. Figure 3 shows the Cox-regression survival curves for different combination of biomarkers. When high levels of NT-proBNP, hs-TnT, and UAE were all present, the adjusted HR was strongly increased: 7.28; 95% confidence interval 3.66 to 14.49; P<0.001 for total new-onset HF.
Discussion
In the present study, we report that an array of biomarkers has limited value in predicting new-onset HF in a large middle-aged cohort from the general population. However, the predictive value for new-onset HF of several cardiovascular biomarkers substantially increased when a high baseline risk group was separately studied. In subjects with low cardiovascular risk, †Adjusted for age, sex, body mass index>30 kg/m 2 , smoking, systolic blood pressure, plasma glucose, and total cholesterol. apart from the established biomarkers NT-proBNP and hs-TnT, no cardiovascular biomarkers were associated with new-onset HFrEF. Finally, regardless of baseline risk group, no biomarkers were associated with new-onset HFpEF, except for cystatin-C, which showed a modest association. Dividing subjects from the general population, based on previous history of cardiovascular disease, seems a useful tool to differentiate high-risk from low-risk individuals. Early detection of increased risk for diagnosis of a high mortality condition such as HFrEF and HFpEF could alert physicians and prompt preventive measures and treatment early in the disease process and may be helpful in attenuating disease progression.
At least 2 large studies have performed multibiomarker analyses for new-onset HF. Velagaleti et al 8 identified NT-proBNP and albumin-to-creatinine ratio to be associated with new-onset HF. Smith et al 9 associated natriuretic peptides with improved risk classification for HF in addition to conventional risk factors. Galectin-3 was recently shown to be associated with increased risk for new-onset HF, on top of conventional risk factors and BNP in the community. 6 Similar to our analyses, these studies provide data from large community-based populations with long-term follow-up and show comparable incidence rates of new-onset HF. However, both previous studies also showed that cardiovascular biomarkers have little or absent incremental value, on top of clinical characteristics, with or without the combination with NT-proBNP to predict new-onset HF. This may be explained by the diversity of subjects at baseline (ie, ethnicity, cardiovascular risk) and lack of power due to a low number of new-onset HF cases. But probably more important, there is increasing evidence of substantial epidemiological differences between subjects with new-onset HFrEF and HFpEF long before time of diagnosis, and these phenotypes should be clearly distinguished. 16, 36 Our analysis adds several novel aspects. To increase the incremental value of several biomarkers, we divided our cohort using a combination of common clinical risk stratification of subjects and performed separate analyses for HFrEF versus HFpEF. We also assessed biomarkers from multiple domains, reflecting different pathological processes that are operative in HF. 37 Figure 2 . A, All biomarkers and their multiadjusted relative risk for new-onset heart failure, divided by risk groups. Heart failure incidence in low-risk group and high-risk group was 168 (2.4%) and 206 (12.2%), respectively. B, All biomarkers and their multiadjusted relative risk for new-onset heart failure with reduced ejection fraction (HFrEF), divided by risk groups. HFrEF incidence in low-risk group and high-risk group was 110 (1.6%) and 131 (7.9%), respectively (Continued). September 2014
Clinical Risk Stratification: High Versus Low Risk at Baseline
Using a simple clinical stratification, commonly used by general practitioners, we incurred large differences in baseline cardiovascular risk (confirmed by the Framingham Risk Score), a substantial shorter follow-up time to incident HF events, and an increased incidence of new-onset HF. We confirm the predictive ability of NT-proBNP for new-onset HF and show increased ability of this biomarker for subjects with high baseline risk compared with subjects with low baseline risk. We also confirm the association between higher circulating galectin-3 concentrations and the increased risk for newonset HF in the general population. 6, 25 However, this seems only significant in subjects with high cardiovascular risk.
Similar results were obtained with novel cardiovascular biomarkers like MR-proANP, MR-proADM, and CT-proET-1, which were only modestly associated with increased risk for developing HF in subjects with high baseline risk. Increased levels of hs-TnT, hs-CRP, cystatin-C, and UAE have been associated with worse prognosis in prevalent HF [38] [39] [40] [41] but did not show differences in HRs between both risk groups. In subjects with low cardiovascular risk at baseline, no novel cardiovascular biomarkers were associated with new-onset HF.
No prospective data have been reported describing the predictive role of atrial natriuretic peptide for new-onset HF to date, although it has been shown that increased atrial natriuretic peptide independently predicts left ventricular hypertrophy in a general population and outcome in patients with chronic HF. 42, 43 Natriuretic peptides showed the strongest prognostic value for new-onset HF, specifically in subjects with high baseline cardiovascular risk. However, the prognostic value of these peptides is not independent of each other. MR-proADM and CT-proET-1, both involved in the homeostasis of the sodium and water balance, have shown promising results in predicting outcome in patients with chronic HF 44, 45 ; however, their incremental value in predicting cardiovascular outcome is still under debate. 9, 46 This might be explained by the fact that both MR-proADM and CT-proET-1 are typically increased in those at risk for cardiovascular disease, such as elderly subjects, with or without chronic kidney disease, albuminuria, or type 2 diabetes mellitus. 23, 44, 47, 48 Through stratification of baseline cardiovascular risk, we were able to improve the ability of these biomarkers to predict new-onset HF.
HFrEF Versus HFpEF
The modest incremental value of biomarkers in previous studies might be partly explained by lack of differentiation between HFrEF and HFpEF, which are known to represent different epidemiological profiles, even years before diagnosis, and could therefore be considered different diseases. 16, 36 Our data not only support this notion but also give new information on the ability of biomarkers to predict either HFrEF or HFpEF. Biomarkers were able to identify subjects at risk for HFrEF, but not HFpEF. This confirms that these phenotypes can not only be regarded as different disease states but also that HFpEF patients are much harder to identify up front. Whether this is caused by specific underlying pathophysiology, the severity of the disease at initial diagnosis, or even the diagnosis itself, should be the focus of future research.
Clinical Implications
Compared with previous large biomarker studies, we have also associated several biomarkers with new-onset HF. However, we must also emphasize the modest predictive value of all evaluated biomarkers in this community-based cohort. By baseline risk stratification, several cardiovascular biomarkers increased the discriminatory power of the statistical model in the high-risk group, in contrast to the low-risk group, where there was overall modest incremental value of all evaluated biomarkers. Out of all possible combinations, the greatest improvement in model fit for high-risk subjects was accomplished with both NT-proBNP and hs-TnT. Screening tactics for the general population, or beneficial effects of individual risk stratification into low-or high-risk groups, needs to be evaluated in future studies, especially for HFpEF. However, from the perspective of cost-effectiveness, we propose to refrain from measuring biomarkers in subjects with low baseline cardiovascular risk. Future studies are needed to evaluate the incremental value of other biomarkers, especially for HFpEF. The large PREVEND cohort, with over 107 000 patient years of follow-up and thoroughly validated cases of new-onset HF, provides good opportunity for large-scale evaluation of biomarkers. We offer a broad range of biomarkers, reflecting multiple domains associated with HF development. In addition, we have identified new-onset HFrEF next to HFpEF, giving insight into pathophysiologic pathways for both HF phenotypes. Our study is limited by the fact that the PREVEND study subjects are predominately white, so our results cannot be extrapolated to subjects of other ethnicity. Serial biomarker data are also not available. Furthermore, we aimed to study differential risk association for HF (and specifically for HFrEF and HFpEF) between low-and high-risk groups and did therefore not include mortality as an additional competing risk state in the current analysis. Finally, the PREVEND cohort was enriched for increased albumin excretion. We therefore conducted design-based analyses, making our results valid for the general population.
Conclusions
In this community-based cohort, several biomarkers were associated with new-onset HF. Risk stratification further increases the incremental value per biomarker to predict HF, especially HFrEF. However, we conclude from our data that routine biomarker testing should be limited to the use of NT-proBNP and hs-TnT in patients with an increased cardiovascular risk. There was no clinically relevant association of any biomarker with new-onset HFpEF, irrespective of risk group.
